Table 1.

Literature review of all clinical cases to date

Authors	Age (y)	Sex	Method of diagnosis and/or type of tissue sampled	ALK detection	Smoking history (pack-years)	Prior treatment	ALK inhibitor	Efficacy
Wang et al. [9]	55	F	Biopsy of the cervical lymph node	IHC, FISH	Non-smoker	PDC	Crizotinib	PR
Mikes et al. [10]	36	M	Bronchial biopsy of the primary lesion	IHC, FISH, RT-PCR	Non-smoker	None	Crizotinib	PR
Zhang et al. [11]	55	F	Bronchial biopsy of the primary lesion	IHC	Non-smoker	PDC	Crizotinib	PR
Vergne et al. [12]	58	F	Bronchial biopsy	IHC, FISH	Non-smoker	PDC	Crizotinib	PR
Tamiya et al. [13]	78	M	Primary lesion	IHC, FISH	49	None	Alectinib	PD
This case	52	F	Bronchial biopsy of the mediastinal lymph node	IHC, FISH	Non-smoker	PDC	Alectinib	PR

ALK anaplastic lymphoma kinase, F female, FISH fluorescence in situ hybridization, IHC immunohistochemistry, M male, PCR polymerase chain reaction, PD progressive disease, PDC platinum-doublet chemotherapy, PR partial response, RT reverse transcription, y year